Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet

Other goals of long-term treatment include reducing the use of steroids for a long period of time and reducing the long-term risk of colorectal cancer (CRC)
Importantly, glucose metabolism and insulin sensitivity were either unchanged or slightly improved, contrasting with the diabetogenic effects of growth hormone
Response: We thank commenters for their support of this proposal
In cartilage biology research, investigators have observed that AOD9604 is associated with proteoglycan synthesis in chondrocyte models, suggesting potential activity in extracellular matrix maintenance
In general, vitamin C strengthens immunity, and vitamin A improves eyesight